ESR1 mutations are present in about 30% of patients with metastatic breast cancer who have received aromatase inhibitors, although only in 5% of breast cancer recurring after adjuvant aromatase inhibitors, and 1% of endocrine therapy-naïve metastatic breast cancer [75]. Here, CYP19A1 is linked to breast carcinoma.